Integrating CAR-T cell therapy into the management of DLBCL: what we are learning

References

• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017Oct 19;130(16): 1800–1808. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588. PMID: 28774879; PMCID: PMC5649550. 10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Gill S, Brudno JN. CAR T-Cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions. Am Soc Clin Oncol Educ Book. 2021 Mar;41(41):1–20. doi: 10.1200/EDBK_320085. PMID: 33989023
   PubMedGoogle Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. AxicabtageneCiloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26): 2531–2544. Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485. 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtageneciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. doi: 10.1016/S1470-2045(18)30864-7
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1): 45–56. Epub 2018 Dec 1. PMID: 30501490. 10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403–1415. Epub 2021 Sep 10. PMID: 34516954. doi: 10.1016/S1470-2045(21)00375-2
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagenemaraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254): 839–852. Epub 2020 Sep 1. PMID: 32888407. 10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Locke FL, Ghobadi A, et al. Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtageneciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(Supplement 1):1764–1764. doi: 10.1182/blood-2021-148078
   Google Scholar
• Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020 Sep 20;38(27): 3095–3106. Epub 2020 Jul 15. PMID: 32667831; PMCID: PMC7499617. 10.1200/JCO.19.02103
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21): 5414–5424. Erratum in: Blood Adv. 2021 Feb 23;5(4):1136. Erratum in: Blood Adv. 2022 Mar 22;6(6):1731. PMID: 33147337; PMCID: PMC7656920. 10.1182/bloodadvances.2020003092
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep 20;38(27): 3119–3128. Epub 2020 May 13. PMID: 32401634; PMCID: PMC7499611. 10.1200/JCO.19.02104
   PubMed Web of Science ®Google Scholar
• Sesques P, Ferrant E, Safar V, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020 Nov;95(11):1324–1333. Epub 2020 Aug 25. PMID: 32744738. doi: 10.1002/ajh.25951
   PubMed Web of Science ®Google Scholar
• Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020 Nov 24;4(22):5607–5615. PMID: 33180899; PMCID: PMC7686887. 10.1182/bloodadvances.2020003001
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as second-line therapy for large B-Cell Lymphoma. N Engl J Med. 2022 Feb;386(7):640–654. doi: 10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. Jun18 2022;399(10343):2294–2308. doi: 10.1016/s0140-6736(22)00662-6
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J Med. 2022 Feb 17;386(7): 629–639. Epub 2021 Dec 14. PMID: 34904798. 10.1056/NEJMoa2116596
   PubMed Web of Science ®Google Scholar
• Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagenemaraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1066–1077. doi: 10.1016/s1470-2045(22)00339-4
   PubMed Web of Science ®Google Scholar
• Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma in transplant-ineligible patients: Primary analysis of Alycante, a phase 2 Lysa Study. Blood. 2022;140(Supplement 1):410–411. doi: 10.1182/blood-2022-156626
   Google Scholar
• Neelapu SS, Dickinson M, Munoz J, et al. Axicabtageneciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 Apr;28(4):735–742. Epub 2022 Mar 21. PMID: 35314842; PMCID: PMC9018426. doi: 10.1038/s41591-022-01731-4
   PubMed Web of Science ®Google Scholar
• Jodon G, Colton MD, Abbott D, et al. Clinical and radiographic Predictors of progression and survival in relapsed/refractory lymphoma patients receiving anti-CD19 CAR T-cell therapy. Clin lymphoma Myeloma Leuk. Epub 2022 Oct 7. PMID: 36335021. 2023 Jan;23(1):49–56. DOI:10.1016/j.clml.2022.09.009
   Google Scholar
• Figura NB, Robinson TJ, Sim AJ, et al. Patterns and Predictors of failure in recurrent or refractory large B-Cell lymphomas after chimeric antigen receptor T-Cell therapy. Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5): 1145–1154. Epub 2021 Jul 6. PMID: 34242714; PMCID: PMC9791939. 10.1016/j.ijrobp.2021.06.038
   PubMed Web of Science ®Google Scholar
• Shouse G, Kaempf A, Gordon MJ, et al. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25;7(14): 3516–3529. PMID: 36735393; PMCID: PMC10362276. 10.1182/bloodadvances.2022009309
   PubMed Web of Science ®Google Scholar
• Iovino L, Wu QV, Voutsinas J, et al. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study. J Cell Mol Med. 2022 Dec;26(24):5976–5983. Epub 2022 Dec 1. PMID: 36453136; PMCID: PMC9753434. doi: 10.1111/jcmm.17550
   PubMed Web of Science ®Google Scholar
• García-Calderón CB, Sierro-Martínez B, García-Guerrero E, et al. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Front Immunol PMID: 37122702; PMCID: PMC10140355 2023 Apr 14;14:1152498. DOI:10.3389/fimmu.2023.1152498
   PubMed Web of Science ®Google Scholar
• Hubbeling H, Silverman EA, Michaud L, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023 Apr;29(4):259.e1–259.e10. Epub 2022 Dec 30. PMID: 36587744; PMCID: PMC10089652. doi: 10.1016/j.jtct.2022.12.021
   PubMedGoogle Scholar
• Albendea MÁ C, Canonico PL, Cartron G, et al. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med PMID: 37324138; PMCID: PMC10263061 2023 May 30;10:1128295. DOI:10.3389/fmed.2023.1128295
   Web of Science ®Google Scholar
• Khurana A, Hathcock MA, Habermann TM, et al. Lines of therapy before autologous stem cell transplant (ASCT) and CAR-T infusion affect outcomes in aggressive non-Hodgkin’s lymphoma (NHL). Blood. 2020;136(Supplement 1):29–30. doi: 10.1182/blood-2020-142511
   Google Scholar
• Dreger P, Dietrich S, Schubert M-L, et al. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. Blood Adv. 2020;4(24):6157–6168. doi: 10.1182/bloodadvances.2020003036
   PubMed Web of Science ®Google Scholar
• Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell Non-Hodgkin Lymphoma: an expert panel opinion from the American Society for transplantation and Cellular therapy. Biol Blood Marrow Transplant. 2019 Dec;25(12):2305–2321. Epub 2019 Aug 22. PMID: 31446199. doi: 10.1016/j.bbmt.2019.08.015
   PubMed Web of Science ®Google Scholar
• Kansagra AJ, Frey NV, Bar M, et al . Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow transplantation (EBMT) and the American Society for Blood and Marrow transplantation (ASBMT). Bone Marrow Transplant. 2019 Nov;54(11):1868–1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15. Erratum in: Bone Marrow Transplant. 2023 Apr;58(4):469. PMID: 31092900; PMCID: PMC8268756
   Google Scholar
• Shaikh S, Shaikh H. CART cell therapy toxicity. Treasure Island (FL). StatPearls Publishing; 2023 Jan [cited 2023 Apr 19]. StatPearls Internet PMID: 37276287.
   Google Scholar
• Gatto L, Ricciotti I, Tosoni A, et al. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Front Oncol PMID: 37397356; PMCID: PMC10312075 2023 Jun 16;13:1206983. DOI:10.3389/fonc.2023.1206983
   PubMed Web of Science ®Google Scholar
• Bhaskar ST, Patel VG, Porter DL, et al. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2022. doi: 10.1182/bloodadvances.2022008937
   Google Scholar
• Yao JM, Otoukesh S, Kim H, et al. Tocilizumab for cytokine release syndrome management after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. Transplant Cell Ther. 2023 Aug;29(8):515.e1–515.e7. Epub 2023 May 12. PMID: 37182736. doi: 10.1016/j.jtct.2023.05.008
   PubMedGoogle Scholar
• Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T – implications for COVID- 19? Blood. 2020;136(1):137–139. position paper. Infection. 2021;49(2):215–231. doi: 10.1182/blood.2020006216
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47–62. Epub 2017 Sep 19. PMID: 28925994; PMCID: PMC6733403. doi: 10.1038/nrclinonc.2017.148
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtageneciloleucel for large B-cell lymphoma. Br J Haematol. 2021 Aug;194(4):690–700. Epub 2021 Jul 22. PMID: 34296427; PMCID: PMC8457222. doi: 10.1111/bjh.17527
   PubMed Web of Science ®Google Scholar
• Abramson J, Palomba ML, Gordon LI, et al. Lisocabtagenemaraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Rossi JF, Chiang H-C, Lu Z-Y, et al. Optimisation of anti-interleukin-6 therapy: precision medicine through mathematical modelling. Front Immunol PMID: 35928820; PMCID: PMC9345304 2022 Jul 19;13:919489. DOI:10.3389/fimmu.2022.919489
   PubMed Web of Science ®Google Scholar
• Park JH, Nath K, Devlin SM, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023 Jul;29(7):1710–1717. Epub 2023 Jul 3. PMID: 37400640. doi: 10.1038/s41591-023-02404-6
   PubMed Web of Science ®Google Scholar
• Gazeau N, Liang EC, Wu Q“, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023 Jul;29(7):430–437. Epub 2023 Apr 7. PMID: 37031746; PMCID: PMC10330552. doi: 10.1016/j.jtct.2023.04.001
   PubMedGoogle Scholar
• London Medicines Information Service. Evidence for use of siltuximab or anakinra as second line therapies (after failure of tocilizumab) for cytokine release syndrome (CRS) following use of chimeric antigen receptor T-cell (CAR-T) therapy. Report, SpecialtyPharmacy Services, (UK), 2019.
   Google Scholar
• Gutierrez C, Brown ART, Herr MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020;58:58–64. doi: 10.1016/j.jcrc.2020.04.008
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–748. doi: 10.1038/s41591-018-0036-4
   PubMed Web of Science ®Google Scholar
• Riegler LL, Jones GP, Lee DW, et al. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323–335. doi: 10.2147/TCRM.S150524
   PubMed Web of Science ®Google Scholar
• Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell–replete peripheral Blood haploidentical donor transplantation is associated with poor survival and anti–IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10):1851–1860. doi: 10.1016/j.bbmt.2016.06.010
   PubMed Web of Science ®Google Scholar
• Galli E, Fresa A, Bellesi S, et al. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): a comprehensive review on incidence, risk factors and current management. Eur J Haematol. Epub ahead of print. PMID: 37491951. 2023 Jul 25. doi:10.1111/ejh.14052
   Web of Science ®Google Scholar
• Rejeski K, Hansen DK, Bansal R, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul 31;16(1): 88. PMID: 37525244; PMCID: PMC10391746. 10.1186/s13045-023-01465-x
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zu C, Jing R, et al. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. Front Immunol PMID: 37215107; PMCID: PMC10192732 2023 May 4;14:1125357. DOI:10.3389/fimmu.2023.1125357
   PubMed Web of Science ®Google Scholar
• Modified immune cells (CD19 CAR T cells) and acalabrutinib for the treatment of relapsed or refractory Mantle cell lymphoma - full text view - ClinicalTrials.Gov.
   Google Scholar
• Arun J, Singh A, Shashidhar E, et al. The ROLE of IMMUNOTHERAPY in CANCER TREATMENT: CHECKPOINT INHIBITORS, CAR-T CELLS, and VACCINES. Georgian Med News. 2023 Jun;(339):105–112. PMID: 37522784.
   PubMedGoogle Scholar
• Tantalo DG, Oliver AJ, von Scheidt B, et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J Immunother Cancer. 2021;9(5):e002555. doi: 10.1136/jitc-2021-002555
   PubMed Web of Science ®Google Scholar
• Sabatino M, Hu J, Sommariva M, et al. Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128(4):519–528. doi: 10.1182/blood-2015-11-683847
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Falcone L, Camisa B, et al. Next-Generation manufacturing Protocols enriching TSCM CAR T cells can Overcome disease-specific T cell Defects in Cancer patients. Front Immunol. 2020;11:1217. doi: 10.3389/fimmu.2020.01217
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li F, Tian Y, et al. Metformin enhances the antitumor activity of CD8+ T lymphocytes via the AMPK–miR-107–eomes–PD-1 pathway. J Immunol. 2020;204(9):2575–2588. doi: 10.4049/jimmunol.1901213
   PubMed Web of Science ®Google Scholar
• Wang Y, Tong C, Dai H, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409. doi: 10.1038/s41467-020-20696-x
   PubMed Web of Science ®Google Scholar
• Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. European Society for Blood and Marrow transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217–1239. Epub 2022 May 19. PMID: 35589997; PMCID: PMC9119216. doi: 10.1038/s41409-022-01691-w
   PubMed Web of Science ®Google Scholar
• Ernst M, Oeser A, Besiroglu B. et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13 9. CD013365 PMID: 34515338; PMCID: PMC8436585 9. 10.1002/14651858.CD013365.pub2
   PubMedGoogle Scholar
• Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139(9):1330–1339. doi: 10.1182/blood.2021013289
   PubMed Web of Science ®Google Scholar
• Lulla PD CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2022Mar 3;139(9):p. 1266–1267. doi: 10.1182/blood.2021014066. Erratum in: Blood. 2022 Dec 15;140(24):2646. PMID: 35238887; PMCID: PMC8900274
   Google Scholar
• Martino M, Canale FA, Naso V, et al. Do CAR-T and allogeneic stem cell Transplant both have a place in lymphoid neoplasms? Int J Mol Sci. 2023 Jan 5;24(2):1045. PMID: 36674573; PMCID: PMC9861434. 10.3390/ijms24021045
   PubMed Web of Science ®Google Scholar
• Killock D. CAR T cells show promise in the frontline for high-risk LBCL. Nat Rev Clin Oncol. 2022 May;19(5):283. doi: 10.1038/s41571-022-00628-y. PMID: 35361894.
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Greco R, Onida F, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant. 2023 Jun;58(6):696–700. Epub 2023 Mar 27. PMID: 36973515; PMCID: PMC10247369. doi: 10.1038/s41409-023-01958-w
   PubMed Web of Science ®Google Scholar
• Ellard R, Kenyon M, Hutt D, et al. The EBMT immune effector cell Nursing guidelines on CAR-T therapy: a framework for patient care and Managing common toxicities. Clin Hematol Int. 2022 Sep;4(3):75–88. Epub 2022 Jul 8. PMID: 36131128; PMCID: PMC9263804. doi: 10.1007/s44228-022-00004-8
   PubMedGoogle Scholar
• Penack O, Peczynski C, Koenecke C, et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant complications Working Party. J Immunother Cancer. 2023 Apr;11(4):e006406. doi: 10.1136/jitc-2022-006406
   PubMed Web of Science ®Google Scholar
• Zhou Y, Mu W, Wang C, et al. Ray of dawn: anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in lymphoma patients. BMC Cancer. 2023 Oct 23;23(1): 1019. PMID: 37872514; PMCID: PMC10591343. 10.1186/s12885-023-11536-4
   PubMed Web of Science ®Google Scholar
• Li C, Xu J, Luo W, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2023 Oct 17. Epub ahead of print. PMID: 37848634. 10.1038/s41375-023-02065-x
   Web of Science ®Google Scholar